In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Teresa Taboada-JaraPharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències (UBNeuro), University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-9666-333X Marta RibaltaPharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències (UBNeuro), University of Barcelona, 08028 Barcelona, Spain.
Fernando Romero-BecerraLaboratory of Medicinal Chemistry, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
Joel MuixíLaboratory of Medicinal Chemistry, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
Aina Bellver-SanchisPharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències (UBNeuro), University of Barcelona, 08028 Barcelona, Spain.
Christian Griñán-FerréPharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències (UBNeuro), University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-5424-9130 Carmen EscolanoLaboratory of Medicinal Chemistry, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.ORCID 0000-0002-9117-8239 Mercè PallàsPharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències (UBNeuro), University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-3095-4254 Funding
Agència de Gestió d'Ajuts Universitaris i de Recerca 2021 SGR 00357Càtedra UB Dr. Antoni Esteve i Subirana de Recerca en FarmacologiaMinisterio de Ciencia, Innovación y Universidades PDC2022-133441-I00Ministerio de Ciencia, Innovación y Universidades PID2022-138079OB-I00Ministerio de Economía y Finanzas and Programa Nacional de Becas "Don Carlos Antonio López" N° 19/2015
6 · The paper itselfAbstract
Neurodegenerative diseases such as Alzheimer's (AD) and Huntington's (HD) remain major therapeutic challenges due to limited treatment efficacy. Imidazoline I2 receptor (I2-IR) ligands have recently emerged as promising neuroprotective agents, with reported roles in modulating oxidative stress, neuroinflammation, and protein aggregation. This study evaluates the therapeutic potential of several I2-IR ligands, including Idazoxan, CR4056, and novel compounds, using
Indexed as
Alzheimer DiseaseCaenorhabditis elegansHuntington DiseaseImidazoline ReceptorsNeuroprotective AgentsAmyloid beta-PeptidesAnimalsAnimals, Genetically ModifiedCaenorhabditis elegans ProteinsDisease Models, AnimalHumansLigandsOxidative StressAmyloid beta-PeptidesCaenorhabditis elegans Proteinsimidazoline receptor 2Imidazoline ReceptorsLigandsNeuroprotective AgentsAlzheimer’s diseaseAβ aggregationC. elegans modelsHt513 aggregatesHuntington’s diseaseimidazoline I2 receptor ligandsneurodegenerationoxidative stresssod-1 gene expression
Identifiers
PMID41977460
PMCPMC13072857
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390